METIS TECHBIO-P's stock plummeted 6.56% intraday, with significant trading volume observed during the session.
The decline reflects a continued post-IPO correction following the stock's 173% surge on its debut. The company, which is in early-stage commercialization, has accumulated substantial losses over the past three years with volatile revenue. Additionally, certain international placement shares were not subject to lock-up restrictions, creating persistent profit-taking pressure as early investors exit positions.
METiS is an AI-driven biotech company specializing in targeted drug delivery using its proprietary NanoForge platform, with capabilities for precision delivery across multiple organs and tissues.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.